Analysis of promoter non-CG methylation in prostate cancer.
Analysis of promoter non-CG methylation in prostate cancer.
复制标题
DOI：
10.2217/epi.12.67
复制
发表时间：
2013-02
期刊：
影响因子：
3.8
通讯作者：
Jarrard DF
中科院分区：
文献类型：
--
作者：
Truong M;Yang B;Wagner J;Desotelle J;Jarrard DF
In vertebrates DNA methylation occurs primarily at CG dinucleotides, but recently non-CG methylation has been found at appreciable levels in embryonic stem cells. To assess non-CG methylation in cancer, we compared the extent of non-CG methylation at several biologically important CpG islands in prostate cancer and normal cell lines. An assessment of the promoter CpG islands Even-skipped homeobox 1 (EVX1) and filamin A-interacting protein 1-like (FILIP1L) demonstrates a 4-fold higher rate of non-CG methylation at EVX1 compared to FILIP1L across all cell lines. These loci are densely methylated at CG sites in cancer. No significant difference in non-CG methylation was demonstrated between cancer and normal. Treatment of cancer cell lines with 5-azacytidine significantly reduced methylation within EVX1 at CG and CC sites preferentially. We conclude that non-CG methylation does not correlate with CG methylation at hypermethylated promoter regions in cancer. Furthermore, global inhibition of DNA methyltransferases does not affect all methylated cytosines uniformly.
